Skip to content

Price / book at other companies

Royalty Pharma logo
Royalty PharmaRPRX
2.1×+0.7×
LQD
Liquidia CorporationLQDA
30.6×+5.3×
Revvity logo
RevvityRVTY
1.4×-0.3×
Roivant Sciences logo
Roivant SciencesROIV
4.4×+2.8×
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
23×+13.5×
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
25.2×+15.2×

Other financials

Income statement

See full
Revenue$51.7M+14.1%
Operating income$17.4M+148%
Net income-$13.3M+68.6%
EPS (diluted)-$0.67+69.7%

Balance sheet

See full
Cash & equivalents$115.1M+140%
Total debt$5.1M+14.2%
Total equity$997.3M+25.4%
Total assets$1.5B+69.2%

Cash flow

See full
Operating cash flow$48.7M+291%
CapEx$228.0K+6.5%
Free cash flow$48.5M+289%

Valuation

See full
Market cap$5.51B+96.7%
Enterprise value$5.4B+95.4%
P/E35.9×
P/S20.1×+4.6×

Profitability

See full
Gross margin91.9%
Operating margin34.5%+23.0pp
Net margin55.9%+35.7pp
FCF margin44.8%+16.8pp

Returns & leverage

See full
Return on equity17.1%+11.5pp
Debt / equity0.0×
Current ratio21.3×+16.0×

Where this comes from

Calculated from Ligand Pharmaceuticals’s reported figures.

Based on the most recent quarter.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ligand Pharmaceuticals's price / book?
Ligand Pharmaceuticals (LGND) reported price / book of 4× in Q1 2026.
How has Ligand Pharmaceuticals's price / book changed year-over-year?
Ligand Pharmaceuticals's price / book increased by 56.9% year-over-year, from 2.5× to 4×.
What is the long-term trend for Ligand Pharmaceuticals's price / book?
Over 5 years (2020 to 2025), Ligand Pharmaceuticals's price / book has grown at a 9.3% compound annual growth rate (CAGR), from 2.3× to 3.7×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.